急性脑梗死患者纤溶酶治疗前后血管内皮和凝血因子的变化  

Changes of vascular endothelium and coagulation factors in patients with acute cerebral infarction before and after plasmin treatment

作　　者：韦日恒 覃海东 黄显仁 韦志祥 江贤智 WEI Riheng;QIN Haidong;HUANG Xianren;WEI Zhixiang;JIANG Xianzhi(Laibin People’s Hospital,Laibin 546100,China)

机构地区：[1]来宾市人民医院,广西来宾546100

出　　处：《中国实用神经疾病杂志》2023年第8期1017-1020,共4页Chinese Journal of Practical Nervous Diseases

摘　　要：目的分析急性脑梗死患者纤溶酶治疗前后血管内皮和凝血因子的变化与临床价值。方法选取2019-03-2022-03于来宾市人民医院治疗的急性脑梗死患者76例为研究组,选同期的健康体检者76例为对照组,比较2组患者的凝血因子和血管内皮相关指标。研究组患者给予纤溶酶治疗,评估其治疗前后的凝血因子、血管内皮因子水平。结果治疗前研究组NO(14.24±4.12)μmol/L、D-D(1.72±0.22)mg/L、ET-1(134.09±12.06)ng/L水平较对照组(6.07±2.01)μmol/L、(0.06±0.01)mg/L、(25.07±6.33)ng/L高,APTT(26.67±2.54)s、PT(11.02±1.42)s水平较对照组(33.35±2.23)s、(13.64±2.87)s低(P<0.05),2组患者TT比较差异无统计学意义(P>0.05)。研究组治疗前后TT对比差异无统计学意义(P>0.05),治疗1 d、3 d后D-D[(1.23±0.19)mg/L、(0.94±0.17)mg/L]、NO[(11.01±3.66)μmol/L、(9.13±3.37)μmol/L]、ET-1[(125.41±30.24)ng/L、(117.46±34.21)ng/L]水平均比治疗前(1.72±0.21)mg/L、(14.24±4.24)μmol/L、(135.09±30.25)ng/L低,APTT[(34.42±2.05)s、(33.88±2.26)s]、PT[(13.62±1.82)s、(13.32±2.06)s]水平均比治疗前(26.67±2.69)s、(11.03±1.41)s高(P<0.05)。结论急性脑梗死患者存在明显的凝血因子、血管内皮因子改变情况,纤溶酶可有效改善患者的凝血功能和血管内皮功能,利于早日康复。Objective To analyze the changes of vascular endothelium and coagulation factor before and after plasminase therapy in patients with acute cerebral infarction and its clinical value.Methods Seventy-six pa⁃tients with acute cerebral infarction in the Laibin People’s Hospital from March 2019 to March 2022 were selec-ted as the study group,and 76 healthy subjects during the same period were selected as the control group.Coagula⁃tion factors and vascular endothelial related indexes of the two groups were observed and compared.The patients in the study group were treated with plasminase,and the levels of coagulation factor and vascular endothelial fac⁃tor before and after treatment were evaluated.Results The levels of NO(14.24±4.12)μmol/L,D-D(1.72±0.22)mg/L,and ET-1(134.09±12.06)ng/L in the study group before treatment were higher than those in the control group[(6.07±2.01)μmol/L,(0.06±0.01)mg/L,(25.07±6.33)ng/L,respectively],APTT(26.67±2.54)s and PT(11.02±1.42)s were lower than those of control group[(33.35±2.23)s,(13.64±2.87)s,respectively](P<0.05),and there was no statistical significance in TT between two groups(P>0.05).There was no significant difference in TT before and after treatment in the study group(P>0.05).One day,three days after treatment,the levels of D-D[(1.23±0.19)mg/L,(0.94±0.17)mg/L,respectively],NO[(11.01±3.66)μmol/L,(9.13±3.37)μmol/L,re⁃spectively],and ET-1[(125.41±30.24)ng/L,(117.46±34.21)ng/L,respectively]in the study group were lower than those before treatment[(1.72±0.21)mg/L,(14.24±4.24)μmol/L and(135.09±30.25)ng/L,respectively].The levels of APTT[(34.42±2.05)s,(33.88±2.26)s,respectively],and PT[(13.62±1.82)s,(13.32±2.06)s,re⁃spectively]in the study group were higher than those before treatment[(26.67±2.69)s,(11.03±1.41)s,respec⁃tively](P<0.05).Conclusion Acute cerebral infarction patients have obvious changes in coagulation factor and vascular endothelial factor,and plasminase therapy can effectively improve the coagulation function and vascular en

关 键 词：急性脑梗死 纤溶酶治疗 血管内皮 凝血因子 

分 类 号：R743.33[医药卫生—神经病学与精神病学]